CSBio CSBio

X
[{"orgOrder":0,"company":"ImmunoBrain Checkpoint","sponsor":"NIA","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"ImmunoBrain Checkpoint Awarded $5 Million US NIA Grant for Phase 1b Alzheimer\u2019s Disease Proof-of-Mechanism Study of Anti-PD-L1 IBC-Ab002","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"ImmunoBrain Checkpoint"},{"orgOrder":0,"company":"SciSparc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SciSparc Announces Israeli Ministry of Health Approval to Conduct its Clinical Trial in Autism Spectrum Disorder","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"SciSparc"},{"orgOrder":0,"company":"SciSparc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SciSparc Receives Approval to Conduct its Clinical Trial in Children with Autism Spectrum Disorder at the Soroka Medical Center","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"SciSparc"},{"orgOrder":0,"company":"SciSparc","sponsor":"Negev Autism Center Soroka University Medical Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SciSparc to Commence its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"SciSparc"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            SCI-210 is a proprietary combination of cannabidiol (CBD), a non-psychoactive cannabinoid, and PEA, clinical trial will investigate SCI-210 in comparison to CBD monotherapy in treating ASD.

            Lead Product(s): Cannabidiol,Cannamide

            Therapeutic Area: Neurology Product Name: SCI-210

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Negev Autism Center Soroka University Medical Center

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 14, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            SCI-210 is a proprietary combination of cannabidiol (CBD), a non-psychoactive cannabinoid, and PEA, clinical trial will investigate SCI-210 in comparison to CBD monotherapy in treating ASD.

            Lead Product(s): Cannabidiol,Cannamide

            Therapeutic Area: Neurology Product Name: SCI-210

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 18, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The trial's objectives are to evaluate the safety, tolerability and efficacy of SCI-210 (cannabidiol) in children and adolescents with ASD in a designed 20-week, randomized, double-blind, placebo controlled with a cross-over clinical trial of 60 children.

            Lead Product(s): Cannabidiol,Cannamide

            Therapeutic Area: Neurology Product Name: SCI-210

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 08, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The grant will be used to support the first-in-human clinical study of IBC-Ab002, a proprietary anti-PD-L1 antibody developed and engineered with differentiating characteristics tailored for the treatment of Alzheimer’s disease.

            Lead Product(s): IBC-Ab002

            Therapeutic Area: Neurology Product Name: IBC-Ab002

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: NIA

            Deal Size: $5.0 million Upfront Cash: Undisclosed

            Deal Type: Funding August 27, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY